-
Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial
•
Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China, has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 therapeutic biologic product, VUM02. This product, derived from human umbilical cord mesenchymal stem cells, is designed…
-
Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China
•
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good Doctor, has entered into a strategic partnership with Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), another Chinese firm. The collaboration aims to combine the business acumen and technical prowess of both companies to…
-
Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment
•
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its VUM02, a Category 1 therapeutic biologic product. This human umbilical cord-derived mesenchymal stem cell therapy is intended…
-
Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial
•
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blind, placebo-controlled Phase I/II study. The study will assess the efficacy and safety of its innovative product VUM02, a…
